Navigation Links
Favrille Announces Resolution of Debt Obligations and Plans for Maximizing Assets
Date:7/7/2008

cility and other assets over the past few weeks," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille. "The future direction of the Company going forward remains uncertain but could include either a reorganization which might involve in-licensing of products contingent upon additional financing, a merger with another entity or liquidation of the Company either inside or outside of bankruptcy. We will continue to explore the relative benefits of all these options. The management and board of directors of Favrille remain committed to addressing these issues and maximizing the value of our assets as expeditiously as possible."

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Favrille's product candidates, proprietary technologies and research and clinical development programs. Such forward- looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to Favrille's ability to continue its operations, conserve cash or recognize value on our assets and additional risks discussed in Favrille's filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement. Favrille is providing this information as of the date of this release and, except as required by law, does not undertake any obligation to update any forward-looking statements containe
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
2. Favrille CEO to Present at Bear Stearns Healthcare Conference
3. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
4. Favrille to Present at BIO InvestorForum
5. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
6. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
7. Favrille Announces $21.1 Million Registered Direct Offering
8. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
9. Favrille to Host Conference Call and Live Webcast to Discuss First Quarter 2008 Financial Results on May 8, 2008
10. Favrille Reports First Quarter 2008 Financial Results
11. Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 •    First of its ... for sustainability ,     New facility will help solve ... , Syngenta unveiled its new crop research ... company’s RTP Innovation Center. The first of its kind, ... simulate any agricultural climate and precisely measure plant inputs ...
(Date:5/17/2013)... Calif. , May 17, 2013 /PRNewswire-iReach/ -- ... has been reached with Switzerland ... of anti-infective human monoclonal antibody (mAb) products, and ... human mAb products for treatment of infections by ... Staphylococcus aureus , Pseudomonas aeruginosa , ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
(Date:5/16/2013)... The Stirling Ultracold Model SU780U ... Athens, OH, USA, won the Outstanding New Product Award ... for Biological and Environmental Repositories (ISBER) at their annual ... product annually, recognizes the company’s development and introduction of ... The award was presented to Global Cooling’s CEO Neill ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
... Eisai Corporation of North,America and its U.S. subsidiary, ... and Drug Administration (FDA) Advisory Committee on Anesthetic,and ... 3 in favor (with one,abstention) of approval of ... agent for sedation in adult patients,undergoing diagnostic or ...
... WALTHAM, Mass., May 7 Interleukin Genetics,Inc. (AMEX: ... conference call and,webcast on Wednesday, May 14, 2008 at ... financial results and provide an update on recent,corporate developments., ... or 719-325-4869,(international). The live webcast will be available on ...
... and Other ... to Nektar, SAN CARLOS, Calif., May 7 ... U.S. Patent and Trademark Office,has issued Patent No. 7,368,102, ... Inhalation Powder (TIP) and other,aminoglycoside antibiotics delivered via Nektar,s ...
Cached Biology Technology:FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation 2FDA Advisory Committee Votes in Favor of Approval of Fospropofol Disodium Injection for Sedation 3Interleukin Genetics Announces Conference Call and Webcast to Discuss First Quarter 2008 Business Results 2Nektar Receives Patent Covering Pulmonary Targeted Antibiotics 2Nektar Receives Patent Covering Pulmonary Targeted Antibiotics 3
(Date:5/16/2013)... FASEB MARC (Maximizing Access to Research Careers) Program ... Society for Developmental Biology (SDB) 72nd Annual Meeting ... awards are meant to promote the entry of ... the mainstream of the basic science community and ... the SDB 2013 Annual Meeting. , Awards are ...
(Date:5/16/2013)... layer lining the body,s blood vessels, is extremely ... thickness, this super-tenuous structure routinely withstands blood flow, ... a unique and highly dynamic barrier that maintains ... body,s circulatory system. , It,s also extremely adaptable. ... breached to enable immune cells to reach ...
(Date:5/16/2013)... fossils that are about 23 million years old ... the gobioid order, one of the most species-rich ... led by paleontologist Professor Bettina Reichenbacher from the ... of Earth and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) ... analysis of fish fossils which they assign to ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... usually a joyous event, but when a child is born too ... baby and steep medical bills for the family. To address this, ... new system to pick up very early signs that a woman ... a pregnancy is 40 weeks, while babies born before 37 weeks ...
... 21 July, 2010 (Vienna, Austria) -- Can HIV infection ... persistence in infected persons was the topic of a ... eve of AIDS 2010, the biennial international conference of ... "Towards a Cure: HIV Reservoirs and Strategies to Control ...
... a new solution to an old debate on why species hybrids ... be published online next week in the online open access journal ... "noise" caused by a surprising degree of variation in gene activity ... that when species hybridise, some of the variation in gene activity ...
Cached Biology News:Students design early labor detector to prevent premature births 2Students design early labor detector to prevent premature births 3Students design early labor detector to prevent premature births 4Top scientists tackle the issue of HIV persistence 2What causes hybrid vigor? 2
MAb to Transferrin Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Rabbit polyclonal to IRS1 (phospho S636) ( Abpromise for all tested applications). entrezGeneID: 3667 SwissProtID: P35568...
Leucine-rich repeat-containing G-protein coupled receptor 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
Biology Products: